Ubs Group Ag Relay Therapeutics, Inc. Transaction History
Ubs Group Ag
- $528 Billion
- Q1 2025
A detailed history of Ubs Group Ag transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 275,558 shares of RLAY stock, worth $1 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
275,558
Previous 343,246
19.72%
Holding current value
$1 Million
Previous $1.41 Million
49.01%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding RLAY
# of Institutions
220Shares Held
163MCall Options Held
153KPut Options Held
49.2K-
Sb Investment Advisers (Uk) LTD London, X027.9MShares$101 Million0.67% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.1MShares$43.9 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct10.8MShares$39.3 Million0.07% of portfolio
-
Black Rock Inc. New York, NY10.5MShares$38.3 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY9.1MShares$33 Million2.79% of portfolio
About Relay Therapeutics, Inc.
- Ticker RLAY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 120,219,000
- Market Cap $436M
- Description
- Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...